A Phase 3 interventional study of PFO closure device and Aspirin and clopidogrel in PFO - Patent Foramen Ovale and Migraine, sponsored by Guangdong Provincial People's Hospital. Completed at 26 sites in China. Open to participants aged 16 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Guangdong Provincial People's Hospital · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Foramen Ovale, Patent with a site in China — 13 open to participants now, 13 under way, none of them phase 3. Foramen Ovale, Patent · China.
Among the 20 studies in Foramen Ovale, Patent with a site in China, this one is the 3rd largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2021, is the only one in phase 3, and was the 5th registered.
137 studies on the registry are indexed under Foramen Ovale, Patent; 47 are open to participants now.
Browse Foramen Ovale, Patent studies →13 of the 20 studies in Foramen Ovale, Patent with a site in China are open now. Recruiting first, the newest first:
First Affiliated Hospital Xi'an Jiaotong University · Sites in China
Ages 18–60
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18+
Sichuan University · Sites in China
Ages 18–60
Chinese Academy of Medical Sciences, Fuwai Hospital · Sites in China
Ages 18–65
China National Center for Cardiovascular Diseases · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 34 Foramen Ovale, Patent studies recruiting now, 11 (32%) set no upper age limit and 19 (56%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 16 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 440 is above the median of 154 across 69 interventional studies indexed under Foramen Ovale, Patent.
Median enrollment 211 across the 14 interventional studies, 565 across the 6 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 20 have an industry lead sponsor. The 10 most frequent:
Guangdong Provincial People's Hospital is the lead sponsor of 237 studies on the registry; 102 are open to participants now.
Guangdong Provincial People's Hospital has 1 study filed under Foramen Ovale, Patent — fewer than ten, so there is no comparison to draw.
4 of the studies in Foramen Ovale, Patent with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06347276China National Center for Cardiovascular DiseasesCerebral Microembolization Associated With PFO Closure | 2026-12-31 |
| NCT06953622Peking University Third HospitalEstablishment of a Clinical and Prognostic Follow-up Cohort of Migraine Patients With Patent Foramen Ovale | 2026-12-31 |
| NCT07170176First Affiliated Hospital Xi'an Jiaotong UniversityEffects of PFO Closure on Glymphatic Function and Clinical Symptoms in Patients With Migraine | 2027-05-31 |
| NCT06863350Sichuan UniversityPercutaneous Repair for Drug - Resistant Epilepsy by Intervention of Closing the Patent Foramen Ovale(PREDICT-PFO Trial) | 2027-06-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 20 studies in Foramen Ovale, Patent with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Migraine is a common neurological disorder that can significantly affect quality of life. Patent foramen ovale (PFO), a small opening between the upper chambers of the heart, has been associated with migraine, but whether closing the PFO can effectively relieve migraine remains uncertain.
This investigator-initiated, multicenter, randomized, open-label trial aims to evaluate the effectiveness and safety of PFO closure in patients with migraine. A total of 440 participants aged 16-60 years with migraine and PFO-associated right-to-left shunt were enrolled at 26 centers in China. Participants were randomly assigned to receive either PFO closure plus antiplatelet therapy or antiplatelet therapy alone.
The primary outcome is complete cessation of migraine during months 10-12 after randomization. Secondary outcomes include changes in migraine frequency, headache-related disability, and quality of life. Participants are followed for 12 months to assess treatment effectiveness and safety.
The criteria were revised on the registry on Nov 12, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants undergo transcatheter PFO closure and receive antiplatelet therapy according to the study protocol.
Device: PFO closure device · Drug: Aspirin and clopidogrel · Drug: Triptans
Participants receive antiplatelet therapy without planned PFO closure during the study period.
Drug: Aspirin and clopidogrel · Drug: Triptans
Device PFO closure.
Drug pages: AspirinStudies of AspirinAspirin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ClopidogrelStudies of ClopidogrelClopidogrel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Aspirin 100mg qd for 6 months and clopidogrel 75mg qd administered for 1month after device implanted.
If migraine recurred, Triptans would be administered during the acute phase.
Complete cessation of migraine
Primary Efficacy Endpoint
Time frame: Months 10-12
Primary Safety Endpoint
Serious adverse event related to the device, medication, or procedure
Time frame: Within 12 Months
Change in Monthly Migraine Attack Frequency
Change in the average number of migraine attacks per month from baseline.
Time frame: Baseline to 12 months after randomization
≥50% Responder rate
Proportion of participants achieving at least a 50% reduction in monthly migraine attack frequency compared with baseline.
Time frame: Baseline to 12 months after randomization.
Change in Headache Impact Test-6 (HIT-6) Score
Change in HIT-6 score from baseline. Scores range from 36 to 78, with higher scores indicating greater headache-related impact.
Time frame: Baseline to 12 months after randomization.
Change in Migraine Disability Assessment (MIDAS) Score
Change in MIDAS score from baseline, assessing migraine-related disability over the preceding 3 months. Higher scores indicate greater disability. This outcome was added through a protocol amendment dated August 3, 2024.
Time frame: Baseline to 12 months after randomization.
Concomitant Medication Use
Assessment of concomitant medications during the study, including acute migraine treatments such as nonsteroidal anti-inflammatory drugs (NSAIDs), triptans, and other migraine-related medications.
Time frame: Baseline through 12 months after randomization.
Residual Right-to-Left Shunt After PFO Closure
Assessment of residual right-to-left shunting following transcatheter PFO closure using contrast-enhanced transcranial Doppler ultrasonography (cTCD) and/or contrast echocardiography.
Time frame: Six months after randomization.
Plan to share: No — The deidentified participant data will be shared on a request basis.
Ran from Aug 2021 to primary completion in Dec 2025, 52 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Sep 2025 → Dec 2025 and completion Sep 2025 → Dec 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Guangdong Provincial People's Hospital →